Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)
| Market Cap | $47.07M-42.0% |
| Revenue (ttm) | $22.89M-25.7% |
| Net Income | -$43.32M-66.5% |
| EPS | -$2.29+33.6% |
| Shares Out | 17.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 127,031 |
| Open | $2.81 |
| Previous Close | $2.88 |
| Day's Range | $2.73 - $2.98 |
| 52-Week Range | $2.73 - $9.82 |
| Beta | 1.67 |
| Analysts | Buy |
| Price Target | $9.00(+228.47%) |
| Earnings Date | Mar 10, 2027 |
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 10, 2027Earnings report
$VRCA stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in VRCA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VRCA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VRCA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VRCA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VRCA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VRCA
| VTIVanguard Morningstar Total Stock Market ETF | $571.39K |
| VXFVanguard Extended Market ETF | $453.81K |
| IWCiShares Micro-Cap ETF | $86.71K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from VRCA’s recent data — informational, not investment advice
What’s Behind the Score
News check: Q3 2026 earnings coverage emphasizes record YCANTH revenue; multiple earnings-focused headlines suggest strong financial performance and business momentum.
